Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.
Document Type
Article
Publication Date
11-1-2017
Abstract
Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rg
Publication Title
Pediatric blood & cancer
ISSN
1545-5017
Volume
64
Issue
11
Recommended Citation
Kinjyo, Ichiko; Ksenia Matlawska-Wasowska; Xiaoru Chen; Noel R Monks; Patricia Burke; Stuart S Winter; and Bridget S Wilson.
"Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.."
Pediatric blood & cancer
